All Episodes
GRACEcast — 299 episodes
FCR vs. BR - Is One Better?
Basics of Small Cell Lung Cancer
Adjuvant Chemotherapy for Elderly and Frail Patients
Rachel Sanborn - Adjuvant Chemotherapy for Early Stage NSCLC Patients, part 1
New Trials of Targeting Therapies to Treat Leptomeningeal Carcinomatosis
ASCO 2016 LC RT Vid 8 - Promising Early Results for Treatments
Immuno-oncology Developments - Combinations and Use as First-Line Therapy
Does Current Evidence Support Favoring Proton-Beam Radiation
J-Alex Trial: Should Alecensa Replace Xalkori as First-Line ALK Therapy?
Are There Less Toxic Alternatives to the Extreme Regimen
Promising Early Data for Oral Inhibitor Buparlisib
Using Immunotherapy as First-Line Treatment and in Combinations
Keynote 55 Pembrolizumab for Heavily Pre-Treated Patients
Using Biomarkers in Immunotherapy
Common Side Effects of PD-1 Inhibitors
Data from Keynote 12 Nivolumab and Pembrolizumab
How Promising Are The Results From Checkmate 141?
Local Consolidation Therapies for Oligomatastases
The Immune System and PD-1 Inhibitors
Urine or Blood Testing Instead of Lung Biopsy Shows Promise for Finding EGFR Mutations
Can Online Patient Groups Speed New Targeted Therapies?
Rova-T Shows Promise in Small Cell Lung Cancer
Significance Of IGHV Mutations & How They Are Assessed
Immunotherapy Combinations
Immunotherapy as First-Line Treatment
Lung Cancer Screening - Process and Potential Benefits
Bronchoscopy and EBUS
Maintenance Therapy for Advanced NSCLC
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC
Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
Histology-Specific Recommendations - Large-Cell Neuroendocrine
Histology-Specific Regimens - Squamous
Histology-Specific Regimens - Adenocarcinoma
What is the Role of Bevacizumab in Stage IV NSCLC?
Platinum-Based Chemo Doublets: Backbone for NSCLC Treatment
Timing of Second Generation ALK Inhibitors: First Line vs. Treatment after Acquired Resistance
CNS Disease in ALK-Positive NSCLC: Monitoring and Systemic vs. Radiation Therapy
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements
ROS-1 Rearrangements: What Are They?
ALK Rearrangements: What Are They, and Who Has Them?
Multiplex Testing for Rare Mutations: What Are the Potential Benefits?
The Role of Targeted Therapy Post-Resection
What Is a Standard Adjuvant Chemotherapy Regimen?
Why Give Adjuvant Chemotherapy, and to Which Patients?
Zoledronate or Denosumab for Lung Cancer with Bone Metastases
How Rate of Progression Can Affect Treatment Decisions
Platinum-Based Doublets As the Cornerstone of First Line Treatment
What are the Goals of Treating Advanced NSCLC?
Video-Assisted Thorascopic Surgery vs. Open Thoracotomy
What Is the Significance of Mediastinal Node Sterilization After Neoadjuvant Therapy?
What Is a Sleeve Resection?
What Is a Mediastinoscopy?
How Do Thoracic Surgeons Assess Fitness for Surgery?
The Surgical Decision: Assessing and Discussing the Patient's Options
Is There a Role for PCI in Locally Advanced NSCLC?
Can Immunotherapy Play a Role in Locally Advanced NSCLC?
Appropriate Chemo Regimens with Radiation for Locally Advanced NSCLC
Is Targeted Therapy Feasible As Consolidation in Locally Advanced NSCLC?
Is There a Role for Induction or Consolidation Chemotherapy Before/After Chemo/Radiation?
Chemoradiation as a Standard of Care for Unresectable NSCLC
What is Stage III Unresectable NSCLC?
Trends in Lung Cancer Demographics and Changes in Histology
Lung Cancer Risk Factors
Lung Cancer Demographics/Epidemiology
Are There Significant Genetic Risks for Lung Cancer?
Local Therapy for Limited Acquired Resistance
Elderly Patients: Selecting Appropriate Systemic Treatment Agents
Elderly Patients: Single Agent vs. Doublet Chemotherapy
The Basics of a Lung Cancer Workup
What Are Pulmonary Function Tests, and How Are They Used?
PET Scan Imaging: What Does It Tell Us?
How a Diagnosis of Lung Cancer is Made: The Biopsy
Potential Advantages, Disadvantages and Limitations of Lung Cancer Screening
Detecting Lung Cancer: Presenting Symptoms
Predictive Testing for Chemotherapy Responsiveness
HER2 Mutation Positive NSCLC
ALK Inhibitors for Acquired Resistance: Zykadia and Alectinib
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC
Third Generation EGFR TKIs for Acquired Resistance
Targeted Therapies in a Post-Operative/Adjuvant Setting
Induction Chemotherapy Followed by Chemo/Radiation for Stage III NSCLC
Management of Locally Advanced NSCLC in the Elderly and Frail
Defining Resectability in Stage IIIA Lung Cancer
Neoadjuvant Chemotherapy vs. Chemo/Radiation for Stage IIIA NSCLC
Overall Management for Stage IIIA Disease
Managing Three Compartments in Stage III Disease (Local, Distant, CNS)
Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC
What is V20 and Why Do Radiation Dose & Field Size Matter?
High vs. Standard Dose Chest Radiation in Stage III Lung Cancer
SBRT for Oligometastatic Lung Cancer
SBRT for Medically Inoperable Stage I Lung Cancer
What is Stereotactic Radiosurgery/Radiation Therapy to the Brain or Body?
What is the Role of Molecular Marker Testing in the Adjuvant or Post-Op Setting?
SBRT as a Potential Alternative for Fit Patients with Early Stage Lung Cancer
Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
Different Lung Cancer Subtypes - Histology
Immunotherapy for Small Cell Lung Cancer
Second Line Chemotherapy Options for SCLC
New Approaches to Immunotherapy
Novel Immunotherapies and Combinations
Blood-Based Mutation Testing: Circulating Tumor Cells and Tumor DNA
Immunotherapy Biomarkers and Patient Selection
What Is Next-Gen Sequencing?
Immunotherapy for Melanoma
Immunotherapy for Lung Cancer
Immunotherapy for Genitourinary Cancers
The Patient Perspective
Immunotherapy for First Line Therapy of Advanced NSCLC
Managing Immunotherapy Side Effects
What is the Optimal Duration of Immunotherapy?
The Current Role of Immunotherapy in the Treatment of Patients with Cancer
Panel Q&A Session on Patient Access and Survivorship
What is Immunotherapy & Its Mechanisms of Action?
Living with Lung Cancer
Access & Assistance for ALK+, ROS1 & EGFR Patients
Panel Q&A Session on Sequencing EGFR Treatments with Drs. Riely and West
Treatment Options for EGFR T790M Negative Acquired Resistance
Emerging Options for T790M-Positive Acquired Resistance
Individual Treatments for Individual EGFR Mutations
Panel Q&A Session on ALK+ and ROS1 Acquired Resistance with Drs. Horn and Owonikoko
The Blood/Brain Barrier for ALK Patients
New Ideas and New Treatment Options for Acquired Resistance for ALK/ROS1
Panel Q&A Session on Acquired Resistance with Drs. Riely & Horn
What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?
Repeat Biopsies and Emerging Techniologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko
Time to Response to Immunotherapy and the Concept of Pseudoprogression
Have Your Practices Changed Regarding Prophylactic Cranial Irradiation for Extensive Stage SCLC Patients?
How Important is the Impact of Smoking Cessation on Survival?
What Are Your Current Practices for Consolidation Chest Radiation for Extensive SCLC?
Are There Clinically Significant Differences Among the Third Generation EGFR Inhibitors?
What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?
The Central Nervous System as a Sanctuary Site: The Special Case for Brain Metastases
Can or Will Specific Molecular Characteristics Help Determine Which ALK Inhibitor to Choose?
Are There Clinically Significant Differences Among the Second Generation ALK Inhibitors?
Can Patients Benefit from Broad vs. Focal Genetic Testing?
Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
What Are the Treatment Choices for EGFR Mutation-Positive Acquired Resistance in Patients Without a T790M Mutation?
Are There Clinically Significant Differences Among the First and Second Generation EGFR TKIs (Iressa, Tarceva, Gilotrif)?
Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?
Should Third Generation EGFR Inhibitors Be Used Before First Generation EGFR TKIs or After Progression?
What Are You Grateful For?
The Lung Cancer Master Protocol/SWOG 1400 as a Clinical Trial for a New Era of Molecular Oncology
Clinical Trial Spotlight: Targeting Brain Mets in EGFR Lung Cancer Patients
In Sickness and In Health
Clinical Trial Spotlight: Can Epigenetic Priming Improve Efficacy of Immunotherapy in NSCLC?
Clinical Trial Spotlight: Identifying Lung Cancer Patients Who Respond to Ponatinib
Postcards from Her Patients
Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance
Clinical Trials of Immune Checkpoint Inhibitors as FIrst Line Therapy for Advanced NSCLC
What is the Current Role of Serum Based Biomarker Testing?
Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
Are Immune Checkpoint Inhibitors Sufficiently Tolerable to Recommend Them for Older or More Frail Patients?
Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?
Is It Feasible and Clearly Beneficial to Combine Immunotherapy Approaches?
Do Clinical Characteristics Alter Your Enthusiasm for Immune Checkpoint inhibitors?
Clinical Trial Spotlight: Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?
Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?
Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?
Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer
Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor?
Clinical Trial Spotlight: Determining Efficacy of Immunotherapy in Stage III Lung Cancer
Clinical Trial Spotlight: ALCHEMIST for Early-Stage ALK+ and EGFR Lung Cancer Patients
Are there Clinically Significant Differences Among Immune Checkpoint Inhibitors Treating Lung Cancer?
Here Today Thanks to Research
First Line Treatment of EGFR Mutation-Positive NSCLC
Promising Early Results with Immunotherapy for Mesothelioma
Grateful for Another Great Year
November is Lung Cancer Awareness Month
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
ECOG 1505 Study: No Benefit of Post-Operative Avastin in Early Stage Lung Cancer Patients
Immunotherapy for Lung Cancer: General Concepts
Should EGFR TKI Therapy be Continued Beyond Progression?
The Potential Value of Repeat Biopsies in Acquired Resistance
Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
Are There Distinctions Among Currently Available Oral EGFR Inhibitors for EGFR Mutation-Positive NSCLC?
Differences Among Specific EGFR Mutations
What is EGFR and the EGFR Mutation?
What is the Value of Testing for Molecular Markers in Advanced NSCLC?
Radiation Management of Limited Stage SCLC
Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer
Prophylactic Cranial Irradiation for Limited Stage Small Cell Lung Cancer
Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?
What is Maintenance Therapy for Advanced NSCLC?
Optimal Systemic Therapy for Bronchioloalveolar Carcinoma (BAC)
Reirradiation of Tumor in a Previously Radiated Field
Cancer Growth Rate and Managing Slow-Growing Lung Cancers
What is a Pancoast Tumor and How is it Best Treated?
Basic Principles of Managing Locally Advanced NSCLC
Pre-Operative/Neoadjuvant Therapy: Rationale and Indications
Surgery Options for Smaller, Slow-Growing Lung Cancers
Immunotherapy for Kidney Cancer Patients in the Front-line Setting: Coming Soon?
Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable Early Stage Lung Cancer
Special Considerations for Lung Cancer Surgery in the Elderly
Challenges of Pneumonectomy Surgery
Types of Lung Surgery: From Wedge Resection to Pneumonectomy
Defining TNM Staging and Early Stage NSCLC
Managing Malignant Pleural Effusions: Pleurodesis
Managing Malignant Pleural Effusions: Tunneled Pleural Catheter
Managing Malignant Pleural Effusions: Thoracentesis
Introduction to Malignant Pleural Effusions
What is the Role of Memantine for Neuroprotection During Whole Brain Irradiation?
Palliative Radiation for Bone Metastases
Liquid Biopsies: Faster Results, Easier on Patients
BRAF: A New Target to Treat in Lung Cancer
Improved Survival in Malignant Pleural Mesothelioma with Avastin Added to Chemotherapy
Which Patients with Lung Cancer Should Receive Whole Brain Radiation Therapy?
Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?
RET in Lung Cancer: The Next Big Target?
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients
Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
Immunotherapy Combinations: Best Balance of Activity and Tolerability?
Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
Immunotherapy for Squamous Non-Small Cell Lung Cancer
Whole Brain Radiation for Brain Metastases
Serum Testing for Molecular Markers: Circulating Tumor Cells & Circulating Free DNA
Myths and Misconceptions About Bronchioloalveolar Carcinoma (BAC)
Bronchioloalveolar Carcinoma (BAC): What is It?
Questions & Answers with Drs. Pal, Luke and Wolchok about Immunotherapy for Cancer
Redefining Success and Failure in Cancer Immunotherapy Trials
The Future of Cancer Immunotherapy: Combination Treatments
The Right Time for Cancer Immunotherapy: Before or After Surgery?
Who Benefits from Immunotherapy?
Lung Cancer Immunotherapy Q&A
Benjamin Levy, MD, Hails 2015 as the Year of Lung Cancer Clinical Trials
Immunotherapy for Lung Cancer: Currently Enrolling Clinical Trials of Combination Therapies
Currently Enrolling Clinical Trials of Single Agent Immunotherapies for Patients with Lung Cancer
What We Know About Immunotherapy Treatments for Lung Cancer
Kidney Cancer Immunotherapy Q&A
Kidney Cancer Immunotherapy: Reasons for Cautious Optimism
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials
Kidney Cancer Immunotherapy: PD-1 Pathway Clinical Trials
Lung Squamous Cancer 201: New Promise in Treatments
Lung Squamous Cancer 201: Understanding Your Disease
Questions & Answers with Drs. Topalian and Wolchok about Immunotherapy for Melanoma
Melanoma Immunotherapy, Pt. 2: The End of the Beginning
Melanoma Immunotherapy, Pt. 1: The End of the Beginning
Immunotherapy for Melanoma, Pt. 2: Immune Checkpoints & the Drugs That Block Them
Immunotherapy for Melanoma, Pt. 1: An Overview
Questions & Answers with Drs. Davies and Atkins, and patient Rusty Cline
Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 2
Why is Immunotherapy More Effective in Some Cancers Than Others? - Part 1
The Patient Perspective
Managing Immunotherapy Side Effects - Part 2
Managing Immunotherapy Side Effects - Part 1
Questions & Answers with Drs. Pardoll, Hellmann, and Luke; Moderated by Dr. West
How Immunotherapy is Administered - Part 2
How Immunotherapy is Administered - Part 1
Dr. Geoffrey Oxnard: My Top Highlight in Lung Cancer from 2014 - Liquid Biopsies
History of Immunotherapy in Cancer - Part 2
History of Immunotherapy in Cancer - Part 1
What is Immunotherapy and its Mechanisms of Action? Part 2
What is Immunotherapy and its Mechanisms of Action? Part 1
Donating to GRACE is Equivalent to a Dose of Hope
It's Possible to Live WITH Cancer
Novel EGFR Inhibitors in the Setting of Acquired Resistance
He Said, She Said - The Doctor/Patient Relationship
Questions & Answers with Bonnie Addario and Craig Uthe; Moderated by Dr. Jack West
The best thing you can do as a cancer patient...
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
Leveraging Patient Engagement & the Role of Advocacy
Questions & Answers with Drs. Doebele and Shaw; Moderated by Craig Uthe
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
Mechanisms of ALK Resistance & Implications for Treatment
Questions & Answers with Drs. Blumenthal and Pennell; Moderated by Dr. West
Using Non/Off-Targeted Therapies in Targeted Lung Cancer Populations
Clinical Trial Design & Development of Highly Targeted Agents in the Molecular Era
Questions & Answers with Drs. Riely, Weiss and Sequist; Moderated by Dr. West
Repeat Biopsies & the Potential Value of Biologically-Informed Acquired Resistance Therapy
Life After 1st Line Targeted Therapy: What Next?
What is Acquired Resistance and How Does it Occur?
Doctors Discuss: Immunotherapy in Lung Cancer
Understanding Acquired Resistance in ALK+ Lung Cancer
Treating Brain Mets in ALK+ Lung Cancer
Are EGFR TKIs (Such as Tarceva) Effective in Lung Cancer Patients Who Are Wild Type EGFR?
Sym-004 Offers Hope for EGFR Wild Type Lung Cancer Patients
It's Time to Get Over the Lung Cancer Stigma
Molecular Testing in Early Stage Non-Small Cell Lung Cancer
Targeted Therapies for Stage III Non-Small Cell Lung Cancer
Small Cell Lung Cancer Clinical Trial: Is ECOG 2511 Right for You?
I'm Very Optimistic. For the First Time.
Do You See Advances in Treatment for Small Cell Lung Cancer in the Near Future?
Will HER2 Inhibitor Drugs Help Lung Cancer Patients?
Treating Leptomeningeal Carcinomatosis in Lung Cancer
What is the Northwestern Medical Developmental Therapeutics Institute?
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow?
Immunotherapy Treatments for Kidney Cancer
Evaluating Biomarkers in Kidney Cancer
Will Combining Immunotherapies Better Fight Kidney Cancer?
Cabozantinib for Late Stage Kidney Cancer
Immunotherapy: What Has a Year’s Experience Taught Us Since ASCO 2013?
The Best Thing You Can Do As a Kidney Cancer Patient
RADIANT and SELECT: Is Adjuvant Erlotinib Effective in Early-Stage Lung Cancer?
Are There PD1 Biomarkers in Kidney Cancer?